Insiders · CHRS

Michael Lee Ryan

Director at Coherus Oncology, Inc. (CHRS) since July 2023

Michael Lee Ryan has filed 5 insider reports with the SEC since July 2023, as director at Coherus Oncology, Inc. (CHRS). The latest filing, on June 9, 2026, reports grant or award at Coherus Oncology, Inc. (CHRS).

Filings
5
Companies
1
Bought on market
None
Sold on market
None

Companies where Michael Lee Ryan is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Coherus Oncology, Inc. logo
CHRS
Coherus Oncology, Inc.
Directorsince July 202330,000$0.3698Jun 9, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael Lee Ryan with

Other insiders at the same companies

Questions about Michael Lee Ryan

What is Michael Lee Ryan's role at Coherus Oncology, Inc.?
Michael Lee Ryan reports to the SEC as director at Coherus Oncology, Inc. (CHRS), according to the latest filing on June 9, 2026.
How many shares does Michael Lee Ryan own?
After the latest filing that states it, Michael Lee Ryan directly owned 30,000 shares of Coherus Oncology, Inc. (CHRS). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Michael Lee Ryan bought or sold stock recently?
No open-market purchases or sales by Michael Lee Ryan are on file. The filings report grant or award.
How do I get alerts when Michael Lee Ryan files?
Follow Michael Lee Ryan on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael Lee Ryan (SEC CIK 0001985918). Totals count each trade once, skipping amendments whose original is on file, from Jul 20, 2023 on. View on SEC EDGAR · Get this as JSON